-->All
Investech see a postive share trend.
LOM Chart
-->All
Merrill Lynch have done a short review of AAA stent graft adverse events reported through the FDA in 2002.
ML report that the US market in 2002 was worth 216M with $153M or 71% going to Medtronic's AneuRx and $63M or 29% going to Guidant and their Ancure device. ML estimate that MDT implanted 12,750 devices with a selling price of $12,000 each and GDT implanted 6300 devices at $10,000 each.
Of the total estimated 19,050 devices implanted there were 480 adverse events reported to the FDA of which 58 were deaths. This gives an adverse event rate of 2.5% for all devices implanted and a death rate of 0.3%. The death rate compares favourably with a typical 4% level for surgical repair but that may include more difficult cases. The death rate for both devices is similar. But the GDT device has overall a higher adverse event rate of 3.6% compared to 2.0% for the MDT device.
Clearly there is room for a safer device in the US market.
Cheers
2Bob